How to administer Emgality1

Preparation

  • Check the pen to be sure it is not expired, damaged, cloudy, discolored, or has particles in it
  • Choose an area for injection (abdomen or thigh if self-injecting or buttocks or back of upper arm if another person is injecting), being sure to choose a different site (even within an area) each month
  • Clean the site with an alcohol wipe and let it dry before injecting

A simple approach: 3 key administration steps

Please review the full Instructions for Use with your patients to ensure they understand how to properly administer Emgality.

1. Uncap the pen

Hands uncapping the pen

2. Place and unlock

Teal button on Emgality pen

3. Press and hold

Hand pressing and holding pen

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Watch how to use the Emgality Pen

Prescribing Information

Patient Information

Instructions for Use

Telephone injection training is also available to help guide your patients through self-administration. Call 1-833-EMGALITY (1-833-364-2548).

SELECT IMPORTANT SAFETY INFORMATION

Adverse Reactions

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Reference

  1. Emgality. Autoinjector Instructions for Use. Lilly USA, LLC.

IMPORTANT SAFETY INFORMATION

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.

Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.

GZ HCP ISI 14SEP2022

INDICATIONS

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache